Effect of Glucocorticoids for the Management of Immune-related Adverse Events on Outcome in Melanoma Patients Treated with Immunotherapy-a Retrospective and Biomarker Study

Overview

Journal Immunooncol Technol

Specialty Allergy & Immunology

Date 2024 Jul 2

PMID 38952418

Authors

F Costa Svedman

M Liapi

A Mansson-Broberg

K Chatzidionysiou

S Egyhazi Brage

Affiliations

Soon will be listed here.

Abstract

Background: Immune-related adverse events (IRAEs) during therapy with immune checkpoint inhibitors (ICIs) are common, and their management sometimes requires glucocorticoids (GCs). Predictors for development of IRAEs and data about the impact of GCs on clinical outcome are missing. We evaluated the impact of GCs to treat IRAEs on clinical outcome, and plasmatic inflammatory proteins as predictors for IRAEs.

Patients And Methods: Patients with melanoma ( = 98) treated with ICIs at Karolinska University Hospital were included. Clinical information and data regarding prescription of systemic GCs were collected. Baseline plasma samples ( = 57) were analyzed for expression of 92 inflammatory proteins.

Results: Forty-four patients developed at least one IRAE requiring systemic GCs and the most common was hypocortisolemia ( = 11). A median overall survival of 72.8 months for patients developing IRAEs requiring GCs, 17.7 months for those who did not, and 1.4 months for individuals receiving GCs at baseline was observed in Kaplan-Meier curves ( = 0.001). In immortal time bias adjusted analysis, patients receiving steroids to treat IRAE survived slightly longer, even though this time trend was not statistically significant. The median overall survival was 29 months for those treated with GCs within 60 days after ICIs start and was not reached for patients receiving GCs later. The number of ICI cycles was higher in subjects receiving GCs after 60 days ( = 0.0053). Hypocortisolemia occurred mainly in males (10/11) and correlated with favorable outcome. Male patients with hypocortisolemia had lower expression of interleukin 8, transforming growth factor-α, and fibroblast growth factor 5 and higher expression of Delta/Notch-like epidermal growth factor-related receptor.

Conclusions: GCs may be used to treat IRAEs without major concern. GCs early during ICIs may, however, impact clinical outcome negatively. The prognostic value of hypocortisolemia and inflammation proteins as biomarkers should be further investigated.

References

Patel S, Othus M, Chen Y, Wright Jr G, Yost K, Hyngstrom J . Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med. 2023; 388(9):813-823. PMC: 10410527. DOI: 10.1056/NEJMoa2211437. View

Robert C, Carlino M, McNeil C, Ribas A, Grob J, Schachter J . Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma. J Clin Oncol. 2023; 41(24):3998-4003. DOI: 10.1200/JCO.22.01599. View

Caturegli P, Di Dalmazi G, Lombardi M, Grosso F, Larman H, Larman T . Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series. Am J Pathol. 2016; 186(12):3225-3235. PMC: 5225294. DOI: 10.1016/j.ajpath.2016.08.020. View

Holmstroem R, Nielsen O, Jacobsen S, Riis L, Theile S, Bjerrum J . COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis. J Immunother Cancer. 2022; 10(9). PMC: 9472120. DOI: 10.1136/jitc-2022-005111. View

Attia P, Phan G, Maker A, Robinson M, Quezado M, Yang J . Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005; 23(25):6043-53. PMC: 1473965. DOI: 10.1200/JCO.2005.06.205. View

Wolchok J, Chiarion-Sileni V, Gonzalez R, Grob J, Rutkowski P, Lao C . Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol. 2021; 40(2):127-137. PMC: 8718224. DOI: 10.1200/JCO.21.02229. View

Hailemichael Y, Johnson D, Abdel-Wahab N, Foo W, Bentebibel S, Daher M . Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022; 40(5):509-523.e6. PMC: 9221568. DOI: 10.1016/j.ccell.2022.04.004. View

Ballester-Lopez C, Conlon T, Ertuz Z, Greiffo F, Irmler M, Verleden S . The Notch ligand DNER regulates macrophage IFNγ release in chronic obstructive pulmonary disease. EBioMedicine. 2019; 43:562-575. PMC: 6562022. DOI: 10.1016/j.ebiom.2019.03.054. View

Larkin J, Ascierto P, Dreno B, Atkinson V, Liszkay G, Maio M . Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014; 371(20):1867-76. DOI: 10.1056/NEJMoa1408868. View

10.

Gershenwald J, Scolyer R . Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond. Ann Surg Oncol. 2018; 25(8):2105-2110. DOI: 10.1245/s10434-018-6513-7. View

11.

Zhao T, Qian K, Zhang Y . High Expression of Is an Independent Prognostic Factor for Poor Overall Survival and Relapse-Free Survival in Lung Adenocarcinoma. J Comput Biol. 2019; 27(6):948-957. DOI: 10.1089/cmb.2019.0241. View

12.

Skribek M, Rounis K, Afshar S, Grundberg O, Friesland S, Tsakonas G . Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. Eur J Cancer. 2021; 145:245-254. DOI: 10.1016/j.ejca.2020.12.012. View

13.

Bjelakovic G, Stojanovic I, Jevtovic Stoimenov T, Pavlovic D, Kocic G, Rossi S . Metabolic correlations of glucocorticoids and polyamines in inflammation and apoptosis. Amino Acids. 2010; 39(1):29-43. DOI: 10.1007/s00726-010-0489-3. View

14.

Romanski N, Holmstroem R, Ellebaek E, Marie Svane I . Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors. Eur J Cancer. 2020; 130:211-218. DOI: 10.1016/j.ejca.2020.02.041. View

15.

Kawai T, Taguchi S, Nakagawa T, Kamei J, Nakamura Y, Obinata D . Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis. J Immunother Cancer. 2022; 10(2). PMC: 8883255. DOI: 10.1136/jitc-2021-003965. View

16.

Horvat T, Adel N, Dang T, Momtaz P, Postow M, Callahan M . Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015; 33(28):3193-8. PMC: 5087335. DOI: 10.1200/JCO.2015.60.8448. View

17.

Long G, Stroyakovskiy D, Gogas H, Levchenko E, De Braud F, Larkin J . Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015; 386(9992):444-51. DOI: 10.1016/S0140-6736(15)60898-4. View

18.

Robert C, Long G, Brady B, Dutriaux C, Maio M, Mortier L . Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2014; 372(4):320-30. DOI: 10.1056/NEJMoa1412082. View

19.

Weber J, Hodi F, Wolchok J, Topalian S, Schadendorf D, Larkin J . Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol. 2017; 35(7):785-792. DOI: 10.1200/JCO.2015.66.1389. View

20.

Arbour K, Mezquita L, Long N, Rizvi H, Auclin E, Ni A . Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. J Clin Oncol. 2018; 36(28):2872-2878. DOI: 10.1200/JCO.2018.79.0006. View